<code id='EE9A9658D7'></code><style id='EE9A9658D7'></style>
    • <acronym id='EE9A9658D7'></acronym>
      <center id='EE9A9658D7'><center id='EE9A9658D7'><tfoot id='EE9A9658D7'></tfoot></center><abbr id='EE9A9658D7'><dir id='EE9A9658D7'><tfoot id='EE9A9658D7'></tfoot><noframes id='EE9A9658D7'>

    • <optgroup id='EE9A9658D7'><strike id='EE9A9658D7'><sup id='EE9A9658D7'></sup></strike><code id='EE9A9658D7'></code></optgroup>
        1. <b id='EE9A9658D7'><label id='EE9A9658D7'><select id='EE9A9658D7'><dt id='EE9A9658D7'><span id='EE9A9658D7'></span></dt></select></label></b><u id='EE9A9658D7'></u>
          <i id='EE9A9658D7'><strike id='EE9A9658D7'><tt id='EE9A9658D7'><pre id='EE9A9658D7'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:688
          Blue Cross Blue Shield website seen on several laptop screens. -- health business coverage from STAT
          Adobe

          A program that undergirds the Affordable Care Act’s health insurance marketplaces continues to bolster the balance sheets of large Blue Cross Blue Shield companies, according to a STAT analysis of new federal data.

          Conversely, that same program — called “risk adjustment” — has created substantial financial burdens for startup insurers including Bright Health Group, which has now exited all health insurance markets, and Friday Health Plans, which has shut down.

          advertisement

          More than two dozen BCBS insurers are projected to collect more than $4.7 billion from competing insurers on the ACA marketplaces, according to the analysis. The biggest amounts are concentrated among a few dominant Blues conglomerates.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more
          Readout Newsletter: Medeor's stem cell study, Moderna's stock dip
          Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

          RogelioV.Solis/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne

          read more
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

          6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

          read more

          Sarepta Duchenne therapy fails to meet primary endpoint in trial

          RubyWallauforSTATSareptaTherapeuticssaidMondayafternoonthatitsgenetherapyforDuchennemusculardystroph